Avrobio News

AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders

TipRanksMar 16 14:01

Avrobio (AVRO) Gets a Buy From Wells Fargo

TipRanksMar 15 18:47

Avrobio Buy Rating: Undervalued Merger Potential With Tectonic and Promising Fc-relaxin Asset for G2PH

TipRanksJan 31 18:50

Mizuho Downgrades Avrobio to Neutral, Lowers Price Target to $2

BenzingaDec 19, 2023 00:36

Avrobio Analyst Ratings

BenzingaDec 19, 2023 00:34

Potential Growth and Strategic Alternatives: Reasons Behind Zhu's Buy Rating for Avrobio

TipRanksNov 13, 2023 18:39

Avrobio (AVRO) Gets a Buy From Barclays

TipRanksAug 11, 2023 16:35

Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating

MT NewswiresJul 13, 2023 21:04

Wells Fargo Maintains Overweight on Avrobio, Lowers Price Target to $2

BenzingaJul 13, 2023 19:56

Avrobio Analyst Ratings

BenzingaJul 13, 2023 19:53

Wedbush Downgrades Avrobio to Neutral, Announces $2 Price Target

BenzingaJul 12, 2023 23:40

Avrobio Analyst Ratings

BenzingaJul 12, 2023 23:38

Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)

TipRanksMay 23, 2023 01:25

Mizuho Securities Keeps Their Buy Rating on Avrobio (AVRO)

TipRanksMay 19, 2023 01:15

Analysts Offer Insights on Healthcare Companies: Avrobio (AVRO), Amylyx Pharmaceuticals Inc (AMLX) and Alcon (ALC)

TipRanksMay 12, 2023 09:40

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Avrobio (AVRO)

TipRanksMay 2, 2023 00:05

Analysts Offer Insights on Healthcare Companies: Alpine Immune Sciences (ALPN), Avrobio (AVRO) and Omega Therapeutics (OMGA)

TipRanksMar 24, 2023 20:27

Mizuho Adjusts Price Target on AVROBIO to $5 From $6, Keeps Buy Rating

MT NewswiresMar 24, 2023 20:25

Morgan Stanley Sticks to Their Hold Rating for Avrobio (AVRO)

TipRanksMar 24, 2023 18:31

Mizuho Securities Keeps Their Buy Rating on Avrobio (AVRO)

TipRanksMar 24, 2023 09:36